Research
Hormonal
Fructose consumption negatively impacts peripheral tissues (gut, muscle, adipose) through interorgan cross-talk, leading to gut dysbiosis, visceral adiposity, and muscle insulin resistance/sarcopenia.
High fructose intake doesn't just hurt the liver; it can worsen gut health, increase belly fat, and reduce muscle insulin sensitivity. Reducing fructose supports whole-body metabolic health.
GoodSupportsHIGH confidence
Excessive fructose consumption is associated, for example, with the release by the liver of several key mediators leading to alterations in the communication between the liver and the gut, muscles, and adipose tissue and to disease aggravation.
Why this rating
Supported by human and animal studies cited in the review.
Source
Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Prasanthi Jegatheesan et al. · Nutrients · 2017
DOI 10.3390/nu9030230
narrative_reviewCited 274×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Excessive fructose consumption promotes nonalcoholic fatty liver disease (NAFLD) by acting as both a substrate and an inducer of hepatic de novo lipogenesis (DNL), leading to lipid accumulation and subsequent oxidative stress and inflammation.Good
- Fructose consumption promotes disease progression from simple steatosis to nonalcoholic steatohepatitis (NASH) by inducing oxidative stress, endoplasmic reticulum (ER) stress, and inflammation via mechanisms including uric acid production and methylglyoxal accumulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →